Centro de Investigación Clínica Bradford Hill - Santiago, Región Metropolitana
Centro de investigación de vanguardia en OncologíaManzano 343, Recoleta, Región Metropolitana, Santiago
Websitehttp://bradfordhill.cl/
Select an option
I am a doctor
I am a sponsor
Specializations
Carcinoma de células renales
Cáncer
Cáncer de hígado
Cáncer de mama
Cáncer de próstata
Cáncer de pulmón
Neumonía
Melanoma
Cáncer de las vías biliares
Carcinoma hepatocelular
Cáncer de origen primario desconocido
Cáncer de vejiga
Cáncer de riñón
Our team
Medical staff
Carlos Rojas Garcia
Carlos Rojas
Mauricio Burotto Pichun
Isabel Saffie
Bárbara Vivanco
Open studies
Lung cancer
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) - MK-2870-004 - Merck Sharp & Dohme LLCSee more
A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) - INTerpath-002 - Merck Sharp & Dohme LLCSee more
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) - MK 2870-007 - Merck Sharp & Dohme LLCSee more
A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant, Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004) - MK-1084-004 - Merck Sharp & Dohme LLCSee more
A Study of Pembrolizumab (MK-3475) With or Without V940 in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) - INTerpath-009 - Merck Sharp & Dohme LLCSee more
Solid tumors
A Study of MK-1084 in KRAS Mutant Advanced Solid Tumors (MK-1084-001) - MK-1084-001 - Merck Sharp & Dohme Corp.See more
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) - Merck Sharp & Dohme LLCSee more
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) - Merck Sharp & Dohme LLCSee more
Breast Cancer
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) - MK-6482-029 LITESPARK-029 - Merck Sharp & Dohme LLCSee more
Colorectal cancer
A Clinical Study of MK-2870 Alone or With Chemotherapy to Treat Gastrointestinal Cancers (MK-9999-02A) - Merck Sharp & Dohme LLCSee more
Endometrial Cancer
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) - MK-2870-005 - GOG FoundationSee more
Head and neck cancer
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma - STELLAR-305 - ExelixisSee more
Kidney cancer
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma - STELLAR-304 - ExelixisSee more
Lymphoma
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) - CC-99282-NHL-001 - CelgeneSee more
Myeloproliferative syndromes
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) - MK-3543-007 - Merck Sharp & Dohme LLCSee more
Prostate cancer
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) - MK-5684-004 - Merck Sharp & Dohme LLCSee more
Skin cancer
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma - REGN3767 - Regeneron PharmaceuticalsSee more
